🇺🇸 FDA
Patent

US 8906853

[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection

granted A61KA61K31/7056A61K31/713

Quick answer

US patent 8906853 ([N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection) held by Enanta Pharmaceuticals, Inc. expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Dec 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/7056, A61K31/713, A61K38/21, A61K45/06